Meet our Team Executive Management Jonathan Cohen President & CEO Mr. Cohen is the founder of our company and has served as Chief Executive Officer, President, and a director since its inception. He is a co-inventor of two of our most successful products, OneTest and BioCheck, and has led the commercial launch and sales of […]
Investor Relations About 20/20 GeneSystems 20/20 GeneSystems, Inc. is a U.S. based privately held corporation based in Maryland. Investment in the company is currently open for Angel, Private and Institutional investors. Investors are invited to review our current Wefunder investment campaign by clicking the link below. Go to Wefunder Campaign 20/20 GeneSystems is offering investments
The Future of Cancer Screening 20/20 GeneSystems pioneers innovative bio-testing and cancer diagnostic tools that address compelling unmet needs. 20/20’s digital diagnostics business develops and commercializes A.I. powered cancer screenings tests deliver better tools to improve early detection of the most common cancers globally. Our emergency bio-detection business includes our patented BioCheck which is widely used by emergency responders.
Welcome to 20/20 GeneSytems Read More »
20/20 GeneSystems (“20/20”) is focused on on reducing cancer deaths worldwide through its years of experience in the development and use of cancer biomarker test development.
